End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug | RE |
2014 | Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Karen Rogers
PRN | Corporate Officer/Principal | - | - |
Sales & Marketing | - | - | |
Corporate Officer/Principal | - | 96-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 06-08-31 | |
Director/Board Member | 70 | 13-09-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,295,299 | 75,907,820 ( 99.49 %) | 0 | 99.49 % |
Company contact information
Cubist Pharmaceuticals LLC
155 Federal Street Suite 700
02110, Boston
+781-860-8660
http://www.cubist.comSector
1st Jan change | Capi. | |
---|---|---|
+0.23% | 91.26B | |
-2.37% | 38.17B | |
+71.42% | 26.74B | |
-12.31% | 15.93B | |
-4.54% | 13.37B | |
-10.83% | 11.77B | |
+180.20% | 10.92B | |
-48.60% | 10.27B | |
+1.42% | 8.69B |
- Stock Market
- Equities
- Stock
- Company Cubist Pharmaceuticals Inc